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ABSTRACT 
Protection from hemolytic uremic syndrome by eyedrop 
vaccination with modified Enterohemorrhagic E. coli  
outer membrane vesicles  
 
Kyoung Sub Choi 
 
Department of Medicine 
The Graduate School, Yonsei University 
 
(Directed by Professor Kyoung Yul Seo) 
 
Enterohemorrhagic E. coli (EHEC) can cause severe diarrhea, hemorrhagic 
colitis, which is often accompanied by hemolytic anemia, thrombocytopenia, 
and acute renal failure. But up until now, specific treatments except public 
health and sanitation are not available. Accordingly, the development of 
effective vaccines preventing EHEC O157:H7 infection is of prime research 
interest. Outer membrane vesicles (OMVs) are spherical membrane blebs 
shed by Gram-negative bacteria and vaccination with OMVs has been 
reported to induce an immune response and protect vaccinated organisms. 
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However, an effective and safe OMV vaccine for protection from EHEC 
O157:H7 infection has not been reported, presumably because OMVs 
generated from EHEC O157:H7 are intrinsically toxic due to presence of 
Shiga toxin (STx) and lipopolysaccharide (LPS) endotoxin. Modified OMVs 
(mOMVs) from cultures of MsbB- and Shiga toxin A subunit (STxA)-
deficient EHEC O157:H7 bacteria have less toxic penta-acylated lipid A 
moiety. Moreover, they do not contain toxic STxA subunit proteins. WaaJ-
mOMVs with additional waaJ mutation do not have the polymeric O-antigen 
of O157 LPS. 
This study is to explore whether eyedrop vaccination using mOMVs and 
waaJ-mOMVs is effective for protecting against hemolytic uremic syndrome 
(HUS) caused by EHEC O157:H7 infection. 
Modified OMVs, waaJ-mOMVs, and mOMVs plus polymyxin B (PMB) 
were administered to BALB/c mice by eyedrop at the onset of experiments. 
Mice were boosted at 2 weeks, and challenged peritoneally with wild-type 
OMVs (wtOMVs) at 4 weeks. In order to increase intestinal mucosal 
immunity, cholera toxins (CT) or polyinosinic:polycytidylic acid (polyI:C) 
were administered with mOMVs. As parameters for evaluation of the 
 3 
 
 
mOMV-mediated immune protection, serum and mucosal immunoglobulins, 
body weight change and blood urea nitrogen (BUN)/Creatinin (Cr) were 
tested, as well as histopathology of renal tissue. Lastly, to confirm the safety 
of mOMVs for eyedrop use, body weight and ocular histopathological 
changes were monitored in mice. 
The mice group vaccinated with mOMVs elicited greater humoral and 
mucosal immune responses than did the waaJ-mOMVs and PBS-treated 
groups. Eyedrop vaccination of mOMVs plus PMB reduced the level of 
humoral and mucosal immune responses. mOMVs plus CT increase systemic 
IgG antibody response and intestinal IgA antibody response. After challenge, 
mice vaccinated with mOMVs were protected from a lethal dose of wtOMVs 
administered intraperitoneally, conversely mice in the PBS control group were 
not.  
In conclusion, the current study showed that eyedrop vaccination using 
mOMVs of EHEC O157 bacteria sufficiently induced immunogenicity in 
mice and intact O157 LPS antigen could be a critical component for 
enhancing the immunogenicity of the mOMVs. Moreover, eyedrop 
vaccination with mOMVs was shown to be effective for preventing HUS 
 4 
 
 
pathogenesis in mice against challenge with HUS-causative wtOMVs and 
thus hold promise for the prevent of EHEC-related pathogenicity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                            
Key words: outer membrane vesicle, Enterohemorrhagic E. coli, eyedrop 
vaccination  
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I. INTRODUCTION 
Enterohemorrhagic E. coli (EHEC) can cause severe diarrhea, hemorrhagic 
colitis, which is often accompanied by hemolytic anemia, thrombocytopenia, 
and acute renal failure, which are the hallmarks of hemolytic uremic 
syndrome (HUS)
1
. Although typical EHEC strains are classified by the 
production of Shiga toxin (STx) and the possession of a locus of enterocyte 
effacement (LEE) in the chromosome, atypical EHEC lacking LEE 
pathogenicity islands can be associated with HUS, as recently witnessed in a 
German outbreak of E. coli O104:H4
2
. Despite the lethal outbreak of HUS 
due to E. coli O104:H4, EHEC O157:H7 remains the most important 
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causative strain involved in the manifestation of HUS worldwide
3
. 
Accordingly, the development of effective vaccines preventing EHEC 
O157:H7 infection-associated HUS is of prime research interest. 
Outer membrane vesicles (OMVs) are spherical membrane blebs shed by 
Gram-negative bacteria
4
. They carry not only native antigens expressed in the 
outer membrane, but also exogenous protein epitopes
5
 and retain self-
adjuvanticity that can be exerted by the inclusion of toll-like receptor agonists 
(lipopolysaccharide, outer membrane lipoproteins, flagellin, etc.)
6
. Several 
reports have demonstrated that vaccination with OMVs is sufficient to induce 
an immune response and protect vaccinated organisms from subsequent 
pathogen challenge
7-10
. However, up until now, an effective and safe OMV 
vaccine for protection from EHEC O157:H7 infection and sequelae HUS has 
not been reported, presumably because OMVs generated from EHEC 
O157:H7 are intrinsically toxic due to presence of STx exotoxin and LPS 
endotoxin, which are two major virulence factors that contribute towards the 
development of HUS. In order to overcome the toxicity of the EHEC O157-
OMVs, detoxified OMV (produced from MsbB- and STxA-deficient mutant) 
was characterized previously for use as a vaccine
5,11
. Moreover, waaJ-
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mOMVs lacking the O-antigen side chains were used to test whether the 
absence of O-antigen in LPS would affect immunogenicity of mOMVs 
administered via an ocular-mucosal route. 
This study is to investigate that eyedrop vaccination with mOMVs of EHEC 
O157:H7 induce humoral and mucosal immune responses and, without the 
use of commercial adjuvants, is able to protect immunized mice from further 
challenge with wtOMVs, which are believed to be produced in the gut of 
EHEC O157-infected hosts and have been suggested as the causative agent 
for HUS
12
. Futhermore, current study is to explore whether loss of the O-
antigen by truncation of O157-LPS to the core region make waaJ-mOMVs 
significantly less immunogenic, indicating the LPS O-antigen in the mOMVs 
plays a significant role in inducing a protective immune response against 
lethal O157-OMV challenge. 
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II. MATERIAL AND METHODS 
 
1. Preparation of mOMVs of EHEC O157:H7 strains 
Modified OMVs and waaJ-mOMVs were kindly provided by Prof. Sang-
Hyun Kim (Korea Research Institute of Bioscience and Biotechnology, 
Ochang, Korea). MsbB- and STxA-deficient mutants of EHEC O157:H7 
(Sakai-DM/stx1A/stx2A)
11
 were used as parental strains for producing 
mOMVs. The ΔwaaJ::Cm allele was introduced into the mOMV-producer 
strain carrying pKD46 by electroporation to create the ΔwaaJ::Cm mutant of 
the mOMV-producer strain. 
 
2. Animals 
This study was performed in strict accordance with the recommendations in 
the Guide for the Care and Use Committee of Yonsei University Health 
System. The committee has reviewed and approved the animal study protocol 
(Approval No: 2011-0261). Specific pathogen-free BALB/c mice, aged 6-10 
weeks, were purchased from Charles River Laboratories (Orient Bio, 
Sungnam, Korea) and were maintained under specific pathogen-free 
conditions in the experimental facility at Yonsei University Health System 
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where they received sterilized food and water ad libitum. All surgeries were 
performed after sacrifice by CO2 narcosis and every effort was made to 
minimize suffering. 
 
3. Immunization with mOMVs and waaJ-mOMVs 
For ocular immunization, five mice were anesthetized and 5 μg mOMVs or 
waaJ-mOMVs suspended in 5 μl PBS were dropped on the conjunctival sac of 
each eye by micropipette. Two weeks after vaccination, mice were boosted by 
the same method. In additional experiments, 5 μg mOMVs plus 5 μg 
polymyxin B (PMB) suspended in 5 μl PBS were immunized on each eye. For 
adjuvants, 5 μg mOMVs plus 1 μg CT or 5 μg polyI:C suspended in 5 μl PBS 
were immunized on each eye. 
 
4. Sample collection 
After intraperitoneal injection of mice with pilocarpine (500 mg/kg body 
weight; Sigma-Aldrich), saliva was obtained. Tear and vaginal wash samples 
were obtained by lavage with 10 μl or 50 μl PBS. Serum was obtained by tail 
venipuncture. Fecal extracts were obtained by adding weighed feces to PBS 
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containing 0.1% sodium azide followed by vortexing. The mixture was then 
centrifuged and the supernatants were collected. 
 
5. Indirect enzyme-linked immunosorbent assay (ELISA) 
ELISA plates (Falcon, Franklin Lakes, NJ) were coated with mOMVs, waaJ-
mOMVs, and wtOMVs, respectively, in PBS and incubated overnight at 4°C. 
Blocking was performed with 1% BSA (Sigma-Aldrich) in PBS, and 2-fold 
serial sample dilutions were applied to plates. HRP-conjugated goat anti-
mouse IgG or IgA (Southern Biotechnology Associates, Birmingham, AL) 
was added to each well and incubated overnight at 4°C. A 
tetramethylbenzidine solution (Moss, Pasadena, MD) was used for color 
development. Plates were measured at 450 nm using an ELISA reader 
(Molecular Devices, Sunnyvale, CA) after the addition of stopping solution 
(0.5N HCl). 
 
6. Protection assay against wild-type OMVs 
Four weeks after eyedrop immunization with mOMVs, 1.5X LD50 of wild-
type EHEC O157:H7 OMVs (LD50 0.274 mg/kg)
11
 were injected 
intraperitoneally for the challenge experiment. Body weight changes were 
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monitored daily for 8 days after injection. For serum sampling by puncturing 
the retro-orbital area, mice were anesthetized by intraperitoneal injection of 
ketamine (100 mg/kg body weight) and xylazine hydrochloride (10 mg/kg 
body weight) and serum was obtained daily for 8 days. Blood samples were 
analyzed for BUN and Cr. For histopathological observation of kidney, a 
survived mouse from each group was sacrificed on day 4 post challenge by 
CO2 narcosis. 
 
7. Histology 
Eye tissues including the conjunctiva and eye balls from PBS control and 
mOMV-treated mice or whole kidney tissues from wtOMV challenged mice 
were washed with PBS and fixed in 4% formaldehyde for 24 h at 4°C. The 
tissues were dehydrated by gradual soaking in alcohol and xylene gradients 
followed by embedding in paraffin. Paraffin-embedded specimens were cut 
into 5-mm sections and stained with H&E. 
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8. Safety evaluation 
In order to confirm the safety of vaccination, some groups of BALB/c mice 
were administered with 10 μg of mOMVs or wtOMVs resolved in 10 μl of 
PBS by eyedrop on both eyes or 10 μg of wtOMVs resolved in 100 μl of PBS 
intraperitoneally. Body weight changes were monitored on a daily basis for 5 
days. Eye tissues were acquired at 24, 48, 72 h after administration of 10 μg 
of mOMVs for histologic examination. 
 
9. Statistical analyses 
All data are expressed as the mean ± SD. Statistical analyses were performed 
by t–tests (Sigma plot). 
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III. RESULTS 
 
1.Characterization of EHEC O157:H7-derived mOMVs and waaJ-
mOMVs 
 
Characteristic molecular patterns of mOMV and waaJ-mOMV was depicted 
(Fig.1). The lipid A portion of LPS lacked a secondary myristate chain in the 
mOMV producing strain due to deficiency of MsbB activity (lipid A 
acyltransferase
13
, Fig. 1A). Similarly, loss of WaaJ activity (an α-1,2-
glucosyltransferase involved in the LPS core biosynthesis
14
) rendered the 
waaJ-mOMV producing strain with truncated LPS consisting of lipid A with 
the core oligosaccharide extended to the galactose residue (Fig. 1A). IB 
analysis of both mOMV types with monoclonal antibodies (anti-STx2A and 
anti-STx2B) showed that mOMVs were STxA-deficient but retained STxB 
subunits (lane 2, Fig. 1B).  
 14 
 
 
 
 
Figure 1 A. Schematic molecular structure of modified outer membrane 
vesicles from EHEC O157:H7 strain. The lipid A portion of LPS lacks the 
secondary myristate chain (red-colored) of the mOMV producing strain due to 
a MsbB deficiency. Lack of WaaJ protein confers the EHEC O157:H7 strain 
with truncated LPS consisting of lipid A with a core oligosaccharide extended 
to the galactose residue.  
 
Figure 1 B. IB analysis of OMVs with monoclonal antibodies (anti-STx2A 
and anti-STx2B). The analysis revealed that the mOMVs (lane 2) were STxA-
deficient, but retained STxB subunits compared to the OMVs of parental 
Sakai-DM strain (lane 1), which produces less endotoxic form of LPS. 
A 
B 
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2. Systemic and mucosal antibody responses  
 
To assess the immunogenicity of eyedrop mOMVs and waaJ-mOMVs 
vaccination, groups of mice were administered with mOMVs and waaJ-
mOMVs by eyedrop instillation. Serum IgG Ab and mucosal IgA Ab levels in 
all vaccinated mice were significantly increased than PBS group. Although 
the levels of both total Ag-specific IgG and IgA Ab of mOMVs vaccinated 
mice were not significantly higher than that of waaJ-mOMVs vaccinated mice, 
mOMVs immunization induced slightly higher Ab production levels than 
waaJ-mOMVs vaccination (Fig. 2A). The immunogenicity continued for 10 
weeks (Fig. 2B). Furthermore, induction of significant enhancement of 
systemic IgG and mucosal IgA antibody production by vaccination of eyedrop 
mOMVs alone without any addition of adjuvant suggested that mOMV nano-
particles could be effective vaccination vehicles by providing major antigens 
(LPS and outer membrane proteins) in their native form without additive 
adjuvants. 
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Figure 2 A. Eyedrop vaccination of mOMVs and waaJ-mOMVs resulted in 
both systemic and mucosal immune responses. Groups of BALB/c mice 
received 5 μg of the mOMVs or waaJ-mOMVs resolved in 5 μl PBS or PBS 
alone by eyedrop on each eye twice at a 2-week interval. mOMVs and waaJ-
mOMVs-specific antibody titers were measured by ELISA in serum and in 
various mucosal secretions at 2 weeks after final vaccination. Results are 
representative of three independent experiments, with five mice in each 
experimental group. *p < 0.05, ** p < 0.01, ***p < 0.001 compared with the 
PBS group. 
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Figure 2 B. Eyedrop vaccination of mOMVs resulted in both systemic and 
mucosal immune responses for 10 weeks. Groups of BALB/c mice received 5 
μg of the mOMVs resolved in 5 μl PBS or PBS alone by eyedrop on each eye 
twice at a 2-week interval. mOMVs-specific antibody titers were measured by 
ELISA in serum and in various mucosal secretions at 8 weeks after final 
vaccination. Results are representative of three independent experiments, with 
five mice in each experimental group. *p < 0.05, ** p < 0.01, ***p < 0.001 
compared with the PBS group. 
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3. Cross reactivity in systemic and mucosal antibody responses  
 
The formation of serum IgG antibodies cross-reactive to wtOMVs was 
confirmed in both mOMVs and waaJ-mOMVs vaccinated groups, and there 
was significantly higher level of mOMVs-specific antibody that cross-reacted 
to wtOMVs, but not in the waaJ-mOMVs group (Fig. 3). 
 
 
Figure 3. Eyedrop vaccination of mOMVs resulted in wtOMVs cross-
reactive Ab production. Groups of BALB/c mice received 5 μg of the 
mOMVs or waaJ-mOMVs resolved in 5 μl PBS or PBS alone by eyedrop on 
each eye twice at a 2-week interval. wtOMVs cross-reactive antibody titers 
were measured by ELISA in serum at 2 weeks after final vaccination. Results 
are representative of three independent experiments, with five mice in each 
experimental group. *p < 0.05 compared with the PBS group. 
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4. Eyedrop vaccination of mOMVs plus PMB blocked immune responses 
in mice 
 
This study evaluated whether premixing mOMVs with polymyxin B (PMB), 
which is known as an endotoxin neutralizing drug, would decrease the 
immunogenic potential of mOMVs. PMB treatment significantly down-
regulated the levels of serum IgG and mucosal IgA Ab in mice vaccinated 
with eyedrop mOMVs (Fig. 4A). However, the levels of LPS-specific 
antibodies were not changed after the addition of PMB (Fig. 4B). These 
results suggest that the LPS component of mOMVs administered via the eye 
mucosa can serve not only as a vaccine antigen itself, but also a natural form 
of strong adjuvant within mOMV vesicle. 
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Figure 4 A,B. Eyedrop vaccination of mOMVs plus PMB blocked immune 
response in mice. Groups of mice given the 5 μg of mOMVs alone or plus 5 
μg of PMB resolved in 5 μl of PBS by eyedrop on each eye twice at a 2-week 
interval. mOMVs- (A) or Anti-LPSO157-specific antibody titers (B) were 
measured by ELISA in serum or in various mucosal secretions at 2 weeks 
after final vaccination. ** p < 0.01, ***p < 0.001 compared with the PBS 
group; § p < 0.05, §§§ p < 0.001 compared with mOMV-vaccinated group. 
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5. Eyedrop vaccination of mOMVs plus adjuvants  
 
 To assess the immunogenicity of eyedrop mOMVs with several adjuvants, 
groups of mice were administered with mOMVs with cholera toxin (CT) or 
polyI:C eyedrop instillation. Eyedrop vaccination of mOMVs with cholera 
toxin (CT) sufficiently induced systemic and mucosal antibody response 
compared to mOMVs alone (Fig. 5A). However, eyedrop vaccination of 
mOMVs with polyI:C did not sufficiently induce antibody response compared 
to mOMVs alone (Fig. 5B). 
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Figure 5 A. Eyedrop vaccination of mOMVs plus CT sufficiently induced 
antibody response in mice. Groups of BALB/c mice received 5 μg of the 
mOMVs alone or plus 1 μg of CT resolved in 5 μl PBS by eyedrop on each 
eye twice at a 2-week interval. mOMVs-specific antibody titers were 
measured by ELISA in serum and in various mucosal secretions at 2 weeks 
after final vaccination. Results are representative of three independent 
experiments, with five mice in each experimental group. *p < 0.05, ** p < 
0.01, ***p < 0.001 compared with the PBS group. § p < 0.05, §§ p < 0.01, 
§§§ p < 0.001 compared with the mOMVs group. 
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Figure 5 B. Eyedrop vaccination of mOMVs plus polyI:C did not sufficiently 
induce antibody response in mice. Groups of BALB/c mice received 5 μg of 
the mOMVs alone or plus 5 μg of polyI:C resolved in 5 μl PBS or PBS by 
eyedrop on each eye twice at a 2-week interval. mOMVs-specific antibody 
titers were measured by ELISA in serum and in various mucosal secretions at 
2 weeks after final vaccination. Results are representative of three 
independent experiments, with five mice in each experimental group. *p < 
0.05, ** p < 0.01, ***p < 0.001 compared with the PBS group. 
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6. Protection efficacy assessed for eyedrop vaccination of the mOMVs 
 
To assess the vaccine efficacy of eyedrop immunization of mice with 
mOMVs, a challenge experiment was performed by intraperitoneal injection 
of lethal dose (1.5X LD50) of wtOMVs. Mice vaccinated with mOMVs 
exhibited a slight loss of body weight (Fig. 6A) and were completely 
protected from challenge with wtOMVs compared to the PBS control group 
(Fig. 6B). We next analyzed BUN and Cr levels in serum of challenged mice. 
The serum levels of BUN and Cr in the mOMVs-vaccinated group were not 
significantly elevated compared with the control group (Fig. 6C,D), and these 
were consistent with histological observations of the renal tissues of mice 
vaccinated with mOMVs which showed virtually no sign of renal bleeding 
compared to that of PBS group (Fig. 6E, right panel). Thus, when results 
above were considered together, the eyedrop mOMVs-vaccination induced 
systemic antibodies against the components of mOMVs which binded and 
neutralized peritoneally injected wtOMVs so that Shiga toxins within 
wtOMVs were blocked in advance and cleared together with wtOMVs. 
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Figure 6 A,B,C,D. Eyedrop vaccination of mOMVs could protect vaccinated 
mice from wtOMVs challenge. For the protection assay, groups of BALB/c 
mice vaccinated with 5 μg of the mOMVs resolved in 5 μl PBS or PBS alone 
by eyedrop on each eye twice at a 2-week interval. At 2 weeks after final 
vaccination, mice were injected with 1.5X LD50 of wild-type EHEC O157:H7 
OMVs (LD50 0.274 mg/kg) intraperitoneally. Body weights (A) and survival 
rates (B) were monitored daily. For the measurement of BUN (C) and 
creatinine (D) levels as indicators of mouse renal function, serum samples 
were acquired from all challenged mice daily. Results are representative of 
three independent experiments, with five mice in each experimental group. *p 
< 0.05 versus PBS group. 
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Figure 6 E. Histopathologic evaluation of renal tissue after wtOMVs 
challenge. For the assessment of renal failure by histological observation, 
renal tissues were sampled from survived mice of each group at 4 days post 
challenge and stained with H&E staining (original magnification X 100). 
 
7. Safety of mOMVs administered by eyedrop 
 
Since the LPS components that present in the mOMVs would have a 
potential to induce an inflammation in administered eyes of mice, the 
possibility of toxicity of eyedrop mOMVs were assessed. Mice were 
administered with 10 μg mOMVs by eyedrop and were monitored for several 
days. As shown in Figure 7, there was no decrease in body weight (Fig. 7A) 
and no histopathological changes in eye mucosa (Fig. 7B). Surprisingly, the 
administration of 10 μg wtOMVs by eyedrop induced no significant reduction 
on mice body weight compared to PBS treated mice, whereas mice that were 
peritoneally injected with the same amount (10 μg) of wtOMVs exhibited a 
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severe loss of body weight and eventually died at 4 days post-injection (Fig. 
7A). Taken together, these results suggest that vaccination of eyedrop 
mOMVs has no toxic effect on eyes, and eye mucosa is an efficient and safe 
vaccine delivery route for inducing protective anti-HUS immunity. 
 
 
 
Figure 7 A. Safety evaluation of eyedrop mOMVs in mice. Groups of 
BALB/c mice were administered with 5 μg of mOMVs or wtOMVs resolved 
in 5 μl of PBS by eyedrop on each eye or 10 μg of wtOMVs resolved in 100 
μl of PBS intraperitoneally. Body weight changes were monitored on a daily 
basis for 5 days. As a control, PBS was administrated via eyedrop. *p < 0.05, 
***p < 0.001 between ocular wtOMV-treated group and intraperitoneally 
wtOMV-treated group. 
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Figure 7 B. Eyedrop mOMVs did not induced ocular inflammation. Eye 
tissues were acquired at 24, 48 and 72 h after administration of 5 μg of 
mOMVs for histologic examination (H&E, original magnification X100). 
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IV. DISCUSSION 
Outer membrane vesicles (OMVs) produced from EHEC O157:H7 Sakai 
strain carried both Shiga toxins and LPS moieties, and caused HUS-like 
symptoms in a mouse model
12
. Thus, OMVs are now recognized as a natural 
HUS-causative agent produced within the guts of patients after infection with 
EHEC O157. Considering that EHEC O157 bacteria are not invasive, it is 
interesting to note that no mechanism other than the proposed OMV package 
delivery has been demonstrated for trans-migration of Shiga toxins and the 
LPS from the gut lumen of HUS patients into the blood stream
12
. This study 
showed that eyedrop vaccination of mOMVs (engineered to be a safe vaccine) 
was effective for preventing HUS pathogenesis in mice challenged with HUS-
causative wtOMVs. Furthermore, loss of LPS O-antigen in the waaJ-mOMVs 
rendered the vesicles much less immunogenic, suggesting that the presence of 
LPS O-antigen in mOMVs is as an important immunogen for inducing 
effective anti-OMVO157 antibodies. 
For the development of an effective vaccine against EHEC-related 
pathogenicity
15,16
, STxB subunit-based immunogens that have ability to 
induce anti-Shiga toxin antibodies have been investigated by several 
laboratories
17-19
. However, no vaccine able to prevent EHEC infection and/or 
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STx-mediated HUS for humans and animals has been reported
17,20
. In the 
preliminary results, sufficiently detectable anti-STxB antibodies by the 
mOMV vaccination could not raised, although anti-STx antibody plays an 
important role in the prevention of HUS, presumably by neutralizing the 
toxins directly. However, the systemic immune responses raised by the 
mOMVs vaccination could protect the mice from the lethal challenge with 
wtOMVs given intraperitoneally. This finding supports previous report
12
 that 
STx toxins are mostly enclosed within the OMVs that carry the cargo from 
the gut where STx is produced to the blood stream (kidney targeting). 
Therefore, it is likely that anti-mOMV antibodies raised by eyedrop 
vaccination can block the spread of the toxin by preventing the OMV 
translocation and/or circulation into the blood stream. 
Mucosal vaccination has numerous merits and thus has gained a great deal of 
attention. Specifically, mucosal vaccination is potentially more convenient 
and inexpensive compared with parenteral vaccines, in that it does not require 
specialized skill for administration, and can stimulate secretion of IgA 
antibodies capable of neutralizing pathogens at sites of entry into the body 
21
. 
Heat-labile toxin (LT) of enterotoxigenic E.coli (ETEC) is well known 
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mucosal vaccine adjuvant; however, intranasal vaccination with LT-
adjuvanted vaccine has raised safety concerns regarding the nervous system 
22
. 
Mucosal vaccination using an ocular route
23-25
 has been shown to effectively 
protect host against diverse array of pathogens
26-29
. Since OMVs of ETEC 
have been reported to induce protective immune responses against 
colonization of ETEC strains in the murine intestine
30
, this study attempted to 
determine whether eyedrop vaccination of mOMVs from EHEC O157 could 
effectively prevent HUS after pathogenic E.coli attack. But eyedrop 
vaccination of the mOMVs could not raise enough gut-mucosal immune 
responses required for lowering the intestinal colonization by the EHEC O157. 
Instead, it could induce protective immune responses preventing systemic 
distribution of the STx-containing OMVs. In the context of local gut-
associated mucosal antibody response, it is worth attempting to test and 
compare the effects of mucosal vaccination performed via nasal, sublingual, 
and oral routes in the further study. Additionally, enhancing the mucosal 
immunity through the addition of optimal adjuvants like CT, the usability of 
mOMVs as the effective mucosal vaccine would be more increased. 
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The experimental eyedrop vaccine model used in this study was intended to 
test whether the mOMV could induce mucosal and/or systemic immune 
responses or not, which is enough to protect the vaccinated animal from the 
lethal HUS-causative agent (wtOMVs), for the first time, via ocular route of 
immunization. Therefore, the intestinal colonization model was not employed 
in this study to evaluate the mOMV-mediated mucosal vaccine effectiveness 
against the EHEC O157 infection in the gut. It will also be interesting to test 
whether mOMVs derived from the Sakai-O157 strain can act as an effective 
vaccine against heterologous EHEC infections. Although, the exposure of the 
R3-core in the LPS lacking the O157 antigen in the waaJ-mOMV can elicit 
the R3-core-specific anti-LPS antibodies that may cross-react to non-O157 
Shiga toxin-producing E. coli (STEC) pathogens possessed with R3-type LPS 
core commonly
31
, this study did not test this possibility that would be another 
theme to be pursued in further experiment. This study has given the prioriy in 
checking out both the formation of neutralizing antibody against mOMVs and 
waaJ-OMVs and the protection against wtOMVs. 
In addition to mOMVs, which consist of the much-less endotoxic LPS 
(penta-acylated lipid A) and are devoid of STxA subunits, this study tested the 
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immunogenicity of waaJ-mOMVs, which are devoid of the O-antigen side 
chains of O157 LPS in the mOMV backbone. O-antigen truncation of LPS of 
bacterial pathogens is often associated with decreased immunogenicity 
compared with full-length LPS
32
. But, sometimes, exposure of the core 
oligosaccharides with O-antigen truncated LPS is supposed to provide 
additional immunogenicity
33
. In the case of waaJ-mOMVs, O-antigen 
truncation rendered the vesicles less immunogenic than the ocular mOMV 
vaccinatioan model, suggesting that O-antigen in mOMVs may serve as a 
strong immunogenic component capable of eliciting an antibody response 
towards the mOMV vaccine. Furthermore, PMB treatment of mOMVs, which 
was used to block the LPS-mediated adjuvant activity of mOMVs
34
, resulted 
in a significant reduction of anti-OMVO157 antibody titers. Interestingly, the 
ability for inducing anti-LPSO157 antibody was not affected by PMB treatment. 
Since PMB binding to LPS of mOMVs by charge-to-charge interactions can 
block TLR-4 dependent innate immunity activation pathways
35
, it has been 
suggested that PMB treatment may decrease the potential adjuvant activity of 
LPS within mOMVs administered to the ocular mucosa. Based on these 
results, LPS moiety of mOMVs served as an adjuvant by promoting 
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immunogenicity of vesicle antigens, but did not contribute towards increased 
production of anti-LPS antibodies. 
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V. CONCLUSION 
The current study showed, for the first time, that eyedrop vaccination using 
mOMVs of EHEC O157 bacteria was efficient vaccination tool which did not 
require additional adjuvants. Moreover, eyedrop vaccination with mOMVs 
was shown to be effective for preventing HUS pathogenesis in mice against 
challenge with HUS-causative wtOMVs. This study also demonstrated that 
loss of LPS O-antigen of waaJ-mOMVs rendered vesicles much less 
immunogenic compared to mOMVs. Thus, taken together, these results 
suggest that mOMV can be utilized as a safe ocular-mucosal vaccine capable 
of inducing a protective immune response against HUS-causative OMVs of 
EHEC O157 bacteria.
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ABSTRACT (in Korean) 
 
장출혈성대장균의 변형외막수포를 이용한 안약백신의 
용혈성요독증후군의 보호효과 
 
<지도교수 서 경 률> 
 
연세대학교 대학원 의학과 
최 경 섭 
 
장출혈성대장균은 설사, 출혈성 장염을 일으키며, 용혈성빈혈, 
혈소판감소증, 급성 신부전 등 심각한 증상과 동반된다. 아직까지 
장출혈성대장균에 대한 치료로 보건 위생학적인 면에서의 조치 
외에는 특별한 치료가 없으며, 최근에는 효과적인 백신의 개발이 
주된 관심 분야로 대두되고 있다. 외막수포는 그람 음성 세균에서 
유래된 구형의 막으로 이를 이용한 백신이 면역반응을 향상시켜 
감염된 개체를 보호할 수 있다는 연구들이 있었다. 그러나 
장출혈성대장균 O157:H7 에서 유래된 외막수포의 경우 Shiga 
toxin 같은 외독소 및 리포다당류 같은 내독소가 존재하기에 
 44 
 
 
효과적이며 안전한 백신으로의 사용이 어려웠다. 이에 반해 MsbB- 
변이와 STxA- 변이가 이루어진 장출혈성대장균에서 유래된 
변형외막수포는 독성이 약화된 penta-acylated 지방 A 구조를 
가지고 있으며, 독성 STxA 단백질을 함유하고 있지 않다. 또한 
waaJ-변형외막수포는 O157 리포다당류의 O-antigen 중합체가 
제거되어 있다. 
본 연구는 용혈성요독증후군에 대한 보호효과를 목적으로 
장출혈성대장균에서 유래된 변형외막수포를 가지고 안약백신의 
효과를 보고자 하였다. 
BALB/c 마우스에 변형외막수포와 waaJ-변형외막수포를 
안약형태로 접종하였다. 2 주 경과후 2 차 접종을 하였으며, 4 주차에 
자연형태 외막수포를 복강내 투여하여 면역 형성 및 보호 효과를 
평가하였다. 또한 장내 점막면역의 효과를 증가 시키기 위하여 
콜레라 독소를 포함한 여러 보조제를 변형외막수포와 함께 
안약형태로 투여하였다. 장출혈성대장균의 변형외막수포 매개 
면역반응을 평가하기 위하여 혈청과 점액에서 면역글로불린을 
ELISA 기법으로 확인하였으며, 보호 효과 평가를 위해 몸무게, 
BUN/Cr 수치의 변화, 신장의 조직병리학적 검사를 하였다. 
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마지막으로 변형외막수포의 안약사용의 안정성을 확인하기 위하여 
마우스의 몸무게와 안구의 조직병리학적인 변화를 확인 하였다. 
변형외막수포로 접종된 마우스에서 전신적, 점막성 면역반응이 
waaJ-변형외막수포 접종군 및 대조군보다 높았다. 변형외막수포에 
polymyxin B 를 더한 경우 전신적, 점막성 면역반응이 감소하였다. 
변형외막수포에 콜레라 독소를 더하여 안약으로 투여시 전신적 및 
장내 항체형성이 증가하였다. 변형외막수포로 안약 점안 시킨 
마우스에서는 복강을 통해 접종된 치사량 용량의 자연형태 
외막수포로부터 보호 되었으며, 대조군에서는 보호 되지 못하였다.  
결론적으로 본 연구는 장출혈성대장균으로부터 유도된 
변형외막수포가 마우스에서 충분한 면역성을 유발함을 확인하였고, 
O157 리포다당류 항원이 외막수포의 면역원성을 향상시키는데 
중요함을 보였다. 더욱이 본 연구는 변형외막수포를 안약형태로 
투여시 장출혈성대장균 관련 용혈요독증후군 유사 증상을 예방할 
수 있었음을 보인 것으로, 향후 장출혈성대장균에 의한 병인의 
예방효과에 대한 기대를 보여준다. 
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